Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NY104 PET Imaging in Renal Cell Carcinoma
NCT05638256Phase 1Unknown
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NYM005 in renal cell carcinoma (RCC), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoints: Evaluation of tissue distribution of 68Ga-NY104 at 1 year and Safety of 68Ga-NY104 at 1 year. Status: unknown.
02
Drugs
68Ga-NYM005
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05638256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638256.